RhoA is commonly activated in the aorta in various hypertensive models, indicating that RhoA seems to be a molecular switch in hypertension. The molecular mechanisms for RhoA activation in stroke-prone spontaneously hypertensive rats (SHRSP) were here investigated using cultured aortic smooth muscle cells (VSMC). 
Introduction
A major determinant of vascular tone is the level of myosin light chain phosphorylation controlled by the balance of the activities between Ca 2 /calmodulin-dependent myosin light chain kinase (MLCK) and myosin phosphatase (MP) (1) . Increased phosphorylation and tension at suboptimal Ca 2 levhumans) by Rho-kinase and the resultant inhibition of MP activity (6, 8) . Another mechanism involves CPI-17, a smooth muscle-specific inhibitory protein for MP (9) . CPI-17 phosphorylation at Thr38 by kinases including protein kinase C (PKC) and Rho-kinase greatly enhances its inhibitory effect on MP (9) (10) (11) . Cyclic nucleotides induce a strong relaxation of smooth muscle, and their potent vasodilator action involves decreasing the Ca 2 sensitization of smooth muscle (referred to as Ca 2 desensitization; for review see Wu et al. (12) ); this phenomenon is thought to be regulated by MP stimulation (3, 4, 13, 14) . The molecular basis for MP activation has not yet been clarified, although it may involve the phosphorylation and inhibition of RhoA by cyclic nucleotide-dependent protein kinases (15) (16) (17) . Accordingly, the Ca 2 sensitization of vascular smooth muscle contraction is regulated both positively and negatively, and the regulation of MP by RhoA/ Rho-kinase plays a central role in this signaling.
Increased vascular resistance is centrally involved in the pathogenesis of hypertension, but the molecular mechanisms leading to this increased resistance are not well determined. Recent studies have reported that Y-27362, a specific Rhokinase inhibitor, dramatically corrected hypertension in various rat hypertensive models but had little effect on normotensive rats, indicating an augmentation of RhoA/Rho-kinase signaling in hypertension (18) . A higher activation of RhoA and an increased expression of RhoA/Rho-kinase in spontaneously hypertensive rats (SHR) could be the underlying mechanisms for the involvement of RhoA/Rho-kinase in hypertension (19, 20) . In addition, a recent report revealed that the RhoA/Rho-kinase pathway was activated in the central nervous system of SHR, and contributed to blood pressure regulation through the sympathetic nervous system (21) . We recently reported that RhoA activation without changes in RhoA/Rho-kinase related molecules was commonly observed in various hypertensive rat models (22) . These data strongly suggest that RhoA/Rho-kinase signaling plays a fundamental role in hypertension.
To investigate the molecular mechanism of RhoA activation in hypertensive rat models, we employed aortic vascular smooth muscle cells (VSMC) of stroke-prone spontaneously hypertensive rats (SHRSP) and examined the molecular mechanisms by which RhoA is preferentially activated in VSMC from SHRSP as compared with those from WistarKyoto rats (WKY). 
Methods

Culture of VSMC
SHRSP and age-matched WKY were obtained from SLC Co., Ltd. (Hamamatsu, Japan). VSMC were isolated by the enzymatic digestion of aortas from 10 to 14-week-old WKY and SHRSP. Cells were cultured in DMEM (Sigma) containing 10% FBS (Biowest, Ringmer, UK), 100 units/ml penicillin and 100 µg/ml streptomycin in 95% O2/5% CO2 at 37 ºC and were used between passages 1 and 3. All these experiments were approved by the Animal Investigation Committee of Mie University School of Medicine.
Preparation of Cell Extracts
Confluent cells were washed twice with phosphate-buffered saline (PBS) and scraped in a modified buffer (50 mmol/l Tris-HCl at pH 7.4, 1% NP-40, 150 mmol/l NaCl, 0.25% w/v Na-deoxycholate, 1 mmol/l EDTA, 0.1% w/v SDS) with protease inhibitors (1 µg/ml aprotinin, 1 µg/ml leupeptin and 1 µmol/l p-amidinophenylmethanesulfonyl fluoride hydrochloride). Cells were lysed using an 18-gauge needle. After centrifugation at 10,000 g for 10 min at 4 ºC, the supernatants were applied to SDS-PAGE and subsequent immunoblotting.
Immunoblot Analysis
Equal amounts of protein were separated by SDS-PAGE and transferred to Immobilon Membranes (Millipore, Bedford, USA). Membranes were blocked for 1 h at room temperature with Tris-buffered saline containing 0.1% Tween-20 and 5% non-fat dry milk. The primary antibodies used in this study were anti-ROKα (BD Transduction Laboratories, Lexington, USA), anti-RhoA (Santa Cruz Biotechnology Inc., Santa Cruz, USA), anti-cyclic AMP (cAMP)-dependent protein kinase (PKA) α catalytic subunit (Santa Cruz Biotechnology Inc.), anti-cyclic GMP (cGMP)-dependent protein kinase Iα (cGKIα) (Calbiochem, San Diego, USA), anti-soluble guanylate cyclase (sGC) β subunit (Cayman Chemical, Ann Arbor, USA), anti-Rho GDP-dissociation inhibitor (RhoGDI) (Santa Cruz Biotechnology Inc.), anti-leukemiaassociated Rho-specific guanine nucleotide exchange factor (RhoGEF) (23), anti-MYPT1 (24), anti-CPI-17 (11) and anti-MLCK (25) antibodies. Immunodetection was accomplished using appropriate horseradish peroxidase-linked secondary antibodies (Amersham, Buckinghamshire, UK) and an enhanced chemiluminescence (ECL) kit (Amersham). The blots were exposed to films (Fuji RX, Tokyo, Japan) for various times to obtain a linear response, and band density was quantified using a Densitograph scanning densitometer (Atto, Tokyo, Japan).
Determination of RhoA Activation
RhoA activation was determined by affinity precipitation of the active GTP-bound RhoA using a glutathione S-transferase (GST)-fusion protein of the Rho-binding domain of Rho effector Rhotekin (GST-RBD) (26) . VSMC, after soaking in serum-free medium for 24-48 h, were lysed with RhoA-RBD buffer (50 mmol/l Tris-HCl at pH 7.2, 1% TritonX-100, 0.5% w/v Na-deoxycholate, 0.1% w/v SDS, 500 mmol/l NaCl, 10 mmol/l MgCl2 with protease inhibitors). The cell lysates were clarified by centrifugation at 10,000 g at 4 ºC for 10 min, and then equal volumes of supernatants were incubated with GST-RBD (20 µg) beads (Upstate Biotechnology, Lake Placid, USA) at 4 ºC for 40 min. The beads were washed three times with wash buffer (50 mmol/l Tris-HCl at pH 7.2, 1% TritonX-100, 150 mmol/l NaCl, 10 mmol/l MgCl2 with protease inhibitors). Bound Rho proteins were detected by immunoblotting using an anti-RhoA antibody.
Measurement of Angiotensin II Level in Rat Tissue
Frozen aortas from SHRSP and WKY were homogenized with a polytron mixer (Kinematica, Luzern, Switzerland) in 4 volumes of 0.1 mol/l HCl, followed by centrifugation at 25,000 g for 30 min at 4 ºC. The supernatants were applied to a Sep-Pak C18 cartridge (Waters Associates, Milford, USA). After washing with 10 ml of 0.1% trifluoroacetic acid in water, peptides were eluted with 3 ml of methanol/ water/trifluoroacetic acid (80/19.9/0.1, v/v). The eluates were dried in a centrifugal concentrator (TOMY, Tokyo, Japan), and the resultant residues were dissolved in 0.1 mol/l Tris-HCl at pH 7.4, followed by radioimmunoassay of angiotensin II (Ang II) performed by SRL Inc. (Tokyo, Japan).
Determination of Phosphorylation Levels of MYPT1
Confluent cells were incubated in serum-free medium for 24 to 48 h. In some experiments, cells were pretreated with Y-27632 (10 µmol/l) for 30 min prior to harvesting cells. Reactions were terminated by the addition of ice-cold trichloroacetic acid to a final 10% w/v and the samples were processed as described previously (8) . The phosphorylation level of MYPT1 at Thr696 was analyzed by immunoblotting using an anti-phospho MYPT1 antibody (pMYPT1 T696 ).
Measurement of cAMP and cGMP Levels
Confluent cells, incubated in serum-free medium for 24 to 48 h, were washed twice in ice-cold PBS, followed by lysing with 1 ml of ice-cold ethanol (70%). After centrifugation at 2,000 g for 15 min, the supernatants were evaporated in a centrifugal concentrator (TOMY). Intracellular cAMP and cGMP levels were measured using Biotrak enzyme assay kits (Amersham). The pellet protein content was determined using a protein assay kit (BioRad, Hercules, USA). The levels of cAMP/cGMP were normalized by the total protein content.
Statistics
All values are expressed as the mean SEM. Data were analyzed by one-way ANOVA or Student's t-test where appropriate. A level of p<0.05 was considered statistically significant.
Results
Activation of RhoA
The level of the GTP-bound active form of RhoA in VSMC from SHRSP was compared with that from WKY by affinity pull-down assay using Rhotekin GST-RBD. As shown in Fig. 1 , the levels of activated RhoA were significantly higher (1.6 0.2 fold, n 6, p<0.01) in SHRSP compared to those in WKY. MYPT1 phosphorylation at Thr696, an inhibitory phosphorylation site by Rho-kinase, was analyzed using a site-and phosphorylation state-specific antibody. MYPT1 phosphorylation levels at Thr696 were significantly increased in SHRSP compared to WKY (1.5 0.1 fold, n 6, p<0.01) (Fig. 2) . Of note, these phosphorylation levels were equally inhibited by treatment with Y-27632 (10 µmol/l) (Fig. 2) . These results suggest that RhoA activation and the resultant phosphorylation of MP by Rho-kinase were enhanced in VSMC from SHRSP.
Expression Level of RhoA/Rho-Kinase Related Molecules
The expression levels of the molecules related to RhoA/Rhokinase signaling in VSMC were investigated by immunoblotting. As shown in Table 1 , there were no significant changes in the expression levels of RhoA, Rho-kinase, MYPT1, CPI-17 or MLCK between SHRSP and WKY cells.
Effect of Valsartan and Prazosin on RhoA Activation
To test whether an endogenous generation of agonists may induce the activation of RhoA in SHRSP, we examined the effect of an Ang II type 1 receptor (AT1) antagonist, valsartan, and an α1-adrenergic receptor antagonist, prazosin, on RhoA activation. As shown in Fig. 3 , valsartan (100 nmol/l, administered for 15 min) significantly decreased the level of the active form of RhoA in VSMC from SHRSP (n 6, p<0.01). On the other hand, prazosin (1 µmol/l, administered for 30 min, n 6) did not affect the activation of RhoA in VSMC from SHRSP (Fig. 3) .
Ang II Contents in the Aorta
The amounts of Ang II in the extract of the aorta from SHRSP were 43 6 pg/g wet tissue (n 4) and those from WKY were under the detection levels (all samples were less than 3 pg/110-220 mg wet tissue, n 4), indicating that the amounts of Ang II in the aorta of SHRSP were significantly ( p<0.05) higher than those of WKY.
Expression of RhoA-Regulating Molecules
Rho GTPase is highly regulated by three classes of proteins, namely guanine nucleotide exchange factors (RhoGEFs), GDP-dissociation inhibitors (RhoGDIs) and GTPase-activating proteins (RhoGAPs) (7). The expression levels of the former two proteins were investigated. As shown in Fig. 4 , the expression levels of RhoGDI and leukemia-associated RhoGEF (LARG), a form of RhoGEF, were not significantly different between SHRSP and WKY cells.
Cyclic Nucleotide Signaling
To analyze cyclic nucleotide signaling in VSMC from SHRSP and WKY, we examined the expression levels of molecules involved in this signaling. As shown in Fig. 5 (Fig. 6 ), although its expression in both VSMCs was markedly depressed to a similar extent after passage 3. There were also no changes in the expression level of sGCβ (Fig. 6 ). Values are expressed as percent relative expression levels of the molecules in SHRSP vs. those in WKY. Data are mean SEM. n 4 to 6. VSMC, vascular smooth muscle cells; MLCK, myosin light chain kinase; SHRSP, stroke-prone spontaneously hypertensive rats.
Fig. 2. MYPT1 phosphorylation level at Thr696 in WKY and SHRSP cells. Representative immunoblots show the phosphorylation level of MYPT1 at Thr696 (top) and the total amount of MYPT1 (middle). Lower densitometrical data represent the mean density of phosphorylated MYPT1 vs. the total MYPT1. The mean density in non-treated WKY is expressed by 1 arbitrary unit. Some cells were treated with Y-27632 (10 µmol/l) for 30 min prior to harvesting of cells.
n 6, p<0.01.
in both VSMCs (Fig. 6 ).
Discussion
The SHR and its close relative SHRSP have been used extensively as models for human essential hypertension.
Many differences in the physiological and molecular properties, such as Ca 2 handling (27, 28) and G proteins (29) , have been reported between these rats and normotensive reference strains, commonly with the implication that such differences are relevant to the pathogenesis of hypertension. In this study we examined the differences in RhoA signaling between SHRSP and WKY, mostly using VSMC derived from their aortae.
The main findings of this study are: 1) The activation of RhoA and the resultant phosphorylation of myosin phos- phatase by Rho-kinase were enhanced in VSMC from SHRSP compared to those from WKY, although the expression levels of RhoA/Rho-kinase related molecules did not change; 2) Valsartan selectively reduced the RhoA activation in SHRSP; 3) cGKIα was downregulated in VSMC from SHRSP compared to those from WKY, while the intracellular cyclic nucleotide contents and the expressions of sGCβ and PKAα were not changed between the two subjects; and 4) There were no significant changes in the expression levels of molecules regulating RhoA, including RhoGDI and LARG.
The RhoA/Rho-kinase pathway plays a key role in the Ca 2 sensitization of smooth muscle contraction, which is mainly induced by MP inhibition (2-5). The possible mechanisms for the RhoA-induced inhibition of MP are via phosphorylation of the MYPT1 subunit at Thr696 (6, 8) and/or that of CPI-17 at Thr38 (9-11). Several lines of evidence suggest that the activation of RhoA/Rho-kinase signaling is involved in vascular smooth muscle hypercontractility as manifested by hypertension, coronary spasm and cerebral vasospasm (30, 31) . In hypertension, Y-27632, a Rho-kinase specific inhibitor, dramatically corrected hypertension in various rat hypertensive models (18) . Another Rho-kinase inhibitor, fasudil, preferentially decreased forearm vascular resistance in hypertensive patients, suggesting that RhoA/Rhokinase signaling is also involved in human hypertension and could be a therapeutic target (32) .
The mechanisms for the activation of Rho-kinase in vascular smooth muscle in hypertensive models have not been fully determined, although several mechanisms, including the increased expression and activation of RhoA (19) and the upregulation of Rho-kinase RNA (20) , have been proposed.
Recently, we determined that higher RhoA activation was commonly detected in the aortas of various hypertensive rat models, namely SHRSP, L-NMAE treated rats, 2-kidney 1-clip renal hypertensive rats and DOCA-salt rats, as compared with normotensive control rats (22) . However, the expression levels of RhoA, Rho-kinase, MYPT1, CPI-17 and MLCK did not differ between the aortas from hypertensive and normotensive rats. In this study, RhoA activation and the increased level of Y-27632-dependent phosphorylation of MYPT1 at Thr696 were observed in serum-depleted SHRSP-derived VSMC, indicating that the same phenomenon (activation of RhoA with no changes in expression of the related molecules) detected in vivo (aorta) was also observed in vitro (cultured VSMC). Thus the molecular mechanisms underlying the activation of RhoA in vitro may be involved, at least in part, in those in vivo.
This study demonstrated that RhoA activation in VSMC from SHRSP was suppressed by an AT1 antagonist, valsartan, but not by an α1-adrenergic receptor antagonist, prazosin. These results suggested that Ang II is involved in the activation of RhoA in VSMC from SHRSP. In VSMC, RhoA is reportedly activated by several agonists, such as serotonin, histamine and Ang II (22, 33) . It has been established that the local renin-angiotensin (RA) system is present in the vascular wall, independent of the circulating RA system, and contributes to the regulation of vessel tone, blood flow and vascular wall cell growth (34) . VSMC from SHR were reported to generate Ang II with increases in angiotensinogen and angiotensin-converting enzyme (35) . These data are consistent with the results in this study obtained using VSMC from SHRSP. It was also shown in this study that Ang II levels were significantly higher in the SHRSP than in the WKY aorta. All these results suggest that the production of Ang II by SHRSP-derived VSMC is one of the factors responsible for the higher activation of RhoA in those cells.
The activity of RhoA itself is regulated by three groups of proteins that are expressed ubiquitously: GTPase-activating proteins (GAPs) stimulate GTP hydrolysis, leading to inactivation; GDP-dissociation inhibitors (GDIs) extract the inactive Rho GTPase from the membrane and prevent nucleotide dissociation and thereby activation; and RhoGEF catalyze nucleotide exchange and mediate activation (7) . Currently, RhoGEFs are regarded as the main regulator of Rho activity. Among RhoGEF proteins, LARG (36), p115RhoGEF (37) and PDZ-RhoGEF (38) could be regulated and activated by an α-subunit of G12/G13, a member of the heterotrimeric G protein family, coupled with RhoA activation (38) (39) (40) (41) . In this study, the expression of RhoGDI and LARG, one of the RhoGEFs ubiquitously expressed, did not differ between SHRSP and WKY cells, suggesting that the expressions of these molecules may not be involved in the RhoA activation in VSMC from SHRSP.
Cyclic nucleotide signaling inhibits RhoA activation, and this signaling seems to be one of the mechanisms for cyclic desensitization of smooth muscle contraction. One of the possible mechanisms for this inhibition is RhoA phosphorylation by cyclic nucleotide-dependent protein kinases. PKA and cGKIα phosphorylate RhoA at Ser188, and inhibit RhoA activation (15) (16) (17) . In vivo and in vitro studies suggest that the Ser188 phosphorylation of RhoA modifies its interaction with RhoGDI and reduces the active GTP-bound form of RhoA (42) . Another significant mechanism occurs through Gα13 phosphorylation at Thr203 by PKA, which leads to RhoA inactivation (43) . In this study, the cAMP content and expression of PKAα did not differ between SHRSP and WKY cells, indicating that the alteration of cAMP signaling may not be involved in RhoA activation in VSMC from SHRSP. Regarding cGMP signaling, the expression of cGKIα was significantly downregulated in SHRSP-derived VSMC, whereas the content of cGMP and the expression level of sGCβ did not significantly change. The downregulation of cGKIα and sGC associated with decreased intracellular cGMP were reported in the aortic ring of SHR (44) . The discrepancies in the contents of sGC and cGMP between this earlier report and our present study may be due to the differences in genetic background (SHRSP vs. SHR) and/or the source of the materials (cultured VSMC vs. aortic rings). Nonetheless, decreased cGMP signaling mediated by the downregulation of cGKIα can be considered to play a role in RhoA activation in VSMC from SHRSP. Figure 7 summarizes RhoA signaling in VSMC and its possible abnormalities in SHRSP. Agonists activate RhoA, which then activates Rho-kinase. Activated Rho-kinase inhibits MP activity, leading to an increase in the level of phosphorylated myosin light chain and the induction of vascular contraction. As shown in this study, RhoA/Rho-kinase signaling is activated in VSMC from SHRSP. The possible mechanisms for RhoA activation include enhanced autocrine/paracrine regulation of endogenous Ang II and/or decreased cGMP signaling induced by the downregulation of cGKIα. These molecular dynamics could activate RhoA, which may contribute to hypertension in SHRSP. However, the in vivo contribution of these molecular dynamics to RhoA activation as well as the involvement of myosin phosphatase inhibition in enhanced vascular tone in SHRSP remains to be investigated. 
